Reliable Biopharmaceutical LLC hires David Feldker

 

Feldker Joins RBC's Board of Directors St. Louis, Missouri – September 27, 2010 - Reliable Biopharmaceutical LLC ("RBC") today announced that David Feldker will join RBC and become its CEO and President effective October 23, 2010. David was previously Vice President SAFC at Sigma-Aldrich Corp. with responsibility for the Active Pharmaceutical Ingredient ("API") contract development and manufacturing segment.

"David built SAFC Pharma into one of the leading developers and manufacturers of High Potency APIs and Biologic Ingredients" said RBC Chairman of the Board James A. Breckenridge. "As RBC continues to grow, David is the perfect executive to lead RBC and capitalize on its complex chemistry capabilities, strong customer relationships as well as its robust API pipeline for generic injectable drugs."

"RBC has built an excellent reputation around high purity ingredients and active pharmaceutical ingredients" said Feldker. "The company has accomplished a great deal over the past few years and I look forward to working together to take it to the next level."

"We are excited about David joining our team" said Vicente Trelles, co-founding partner of Med Opportunity Partners, LLC. "David is an outstanding executive and his experience and leadership in managing a multimillion dollar business will be key to RBC's success."

Mike Zaleski will be stepping down as RBC's President and CEO effective October 22, 2010 but remain an advisor to the RBC Board of Directors during the transition.


Copyright © 2017 Reliable Biopharmaceutical Corporation